Clobazam for refractory focal epilepsy. A controlled trial.
Clobazam for refractory focal epilepsy. A controlled trial.
复制标题
氯巴占用于治疗难治性局灶性癫痫。
作者：
D. Schmidt;M. Rohde;P. Wolf;U. Roeder
在20例最大耐受日剂量标准抗癫痫药物治疗无法控制的慢性复杂部分性癫痫发作患者中进行了一项双盲添加试验，评估了1，5-苯二氮卓类氯巴占的作用。在三个月的积极治疗期间，癫痫发作次数较低。在第三个月结束时，8名（40%）患者的癫痫发作减少了75%以上，其中4名患者（20%）完全控制。在56%的患者中观察到氯巴占抗癫痫作用的耐受性，40%的患者发生轻度一过性镇静。尽管存在这些缺点，氯巴占仍是治疗难治性局灶性癫痫个体患者的有效添加药物。
The effect of 1,5-benzodiazepine clobazam was assessed in a double-blind add-on trial in 20 patients with chronic complex partial seizures uncontrolled by maximally tolerable daily dosage of standard antiepileptic drug therapy. The number of seizures was lower during the three months of active treatment. At the end of the third month, eight (40%) of the patients had a seizure reduction by more than 75%, including four patients (20%) who had complete control. Tolerance to the antiepileptic effect of clobazam was noted in 56% of the patients, and mild transient sedation occurred in 40% of the patients. Despite these drawbacks, clobazam is an effective add-on drug for individual patients with refractory focal epilepsy.